絞り込み

16402

広告

783件中 1件~20件表示    検索結果をPubMedで見る PubMedで見る

The activation of SRC family kinases and focal adhesion kinase with the loss of the amplified, mutated EGFR gene contributes to the resistance to afatinib, erlotinib and osimertinib in human lung cancer cells.

Healthcare costs in patients with advanced non-small cell lung cancer and disease progression during targeted therapy: a real-world observational study.

Identification of genome variations in patients with lung adenocarcinoma using whole genome re‑sequencing.

Substrate-dependent effects of molecular-targeted anticancer agents on activity of organic anion transporting polypeptide 1B1.

Targeting non-small cell lung cancer with small-molecule EGFR tyrosine kinase inhibitors.

Afatinib treatment of a squamous lung cancer after tumor progression of nivolumab.

[Hyponatremia in a 58-year-old female patient with EGFR-positive lung adenocarcinoma].

Acquisition of the T790M resistance mutation during afatinib treatment in EGFR tyrosine kinase inhibitor-naïve patients with non-small cell lung cancer harboring EGFR mutations.

Clinical strategies for acquired epidermal growth factor receptor tyrosine kinase inhibitor resistance in non-small-cell lung cancer patients.

EGFR or HER2 inhibition modulates the tumor microenvironment by suppression of PD-L1 and cytokines release.

Phase I study of induction chemotherapy with afatinib, ribavirin, and weekly carboplatin and paclitaxel for stage IVA/IVB human papillomavirus-associated oropharyngeal squamous cell cancer.

Dual MET and ERBB inhibition overcomes intratumor plasticity in osimertinib-resistant-advanced non-small-cell lung cancer (NSCLC).

Biomarkers predict enhanced clinical outcomes with afatinib versus methotrexate in patients with second-line recurrent and/or metastatic head and neck cancer.

Successful targeting of the NRG1 pathway indicates novel treatment strategy for metastatic cancer.

Chinese Medicine Treatment for Afatinib-Induced Paronychia.

Afatinib Therapy for Brain Metastasis Aggravated by a Reduction in the Dose of Erlotinib Due to the Development of Hepatotoxicity.

Change from lung adenocarcinoma to small cell lung cancer as a mechanism of resistance to afatinib.

Multiple receptor tyrosine kinase activation related to ALK inhibitor resistance in lung cancer cells with ALK rearrangement.

Cx32 inhibits TNFα-induced extrinsic apoptosis with and without EGFR suppression.

AKT can modulate the in vitro response of HNSCC cells to irreversible EGFR inhibitors.

  1. 1
  2. 2
  3. 3
  4. 4
  5. 5
  6. 6
  7. 7
  8. 8
  9. 9
  10. 10
Sort by
※並べ替えは表示に時間がかかります